Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
December 17, 2024 07:00 ET
|
Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
December 11, 2024 07:00 ET
|
Immunocore Holdings plc
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
December 03, 2024 01:00 ET
|
Immunocore Holdings plc
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...
Immunocore to present at upcoming investor conferences
November 08, 2024 07:00 ET
|
Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...
Immunocore reports third quarter financial results and provides a business update
November 06, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq:...
Immunocore announces transition of Chief Financial Officer
August 29, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore announces transition of Chief Financial Officer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 29 August 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
Immunocore reports second quarter financial results and provides a business update
August 08, 2024 07:00 ET
|
Immunocore Holdings plc
KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing,...
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
August 01, 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 August 2024) Immunocore...